Keel Point LLC decreased its position in Pfizer, Inc. (NYSE:PFE) by 1.2% during the first quarter, Holdings Channel reports. The fund owned 18,833 shares of the biopharmaceutical company’s stock after selling 232 shares during the period. Keel Point LLC’s holdings in Pfizer were worth $644,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. Asset Planning Services Ltd. increased its position in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 137 shares during the last quarter. Orrstown Financial Services Inc. increased its position in shares of Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 612 shares during the last quarter. Cable Hill Partners LLC increased its position in shares of Pfizer by 6.0% in the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 265 shares during the last quarter. D Orazio & Associates Inc. increased its position in shares of Pfizer by 0.5% in the fourth quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 28 shares during the last quarter. Finally, Acropolis Investment Management LLC increased its position in shares of Pfizer by 1.9% in the first quarter. Acropolis Investment Management LLC now owns 5,251 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 70.10% of the company’s stock.

Shares of Pfizer, Inc. (NYSE PFE) traded up 0.03% on Friday, reaching $33.43. 4,213,903 shares of the company’s stock traded hands. The company has a 50 day moving average price of $33.43 and a 200 day moving average price of $33.30. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $35.38. The firm has a market capitalization of $199.51 billion, a price-to-earnings ratio of 24.46 and a beta of 1.00.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.02. The business had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.11%. The firm’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same period last year, the firm posted $0.64 earnings per share. On average, equities research analysts predict that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 3.83%. The ex-dividend date is Wednesday, August 2nd. Pfizer’s dividend payout ratio (DPR) is currently 94.12%.

ILLEGAL ACTIVITY WARNING: “Keel Point LLC Has $644,000 Stake in Pfizer, Inc. (NYSE:PFE)” was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/keel-point-llc-has-644000-stake-in-pfizer-inc-nysepfe/1475416.html.

A number of equities analysts recently commented on the stock. Berenberg Bank set a $39.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, August 1st. Jefferies Group LLC set a $35.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. BidaskClub upgraded shares of Pfizer from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 5th. UBS AG reiterated a “buy” rating and set a $38.00 target price on shares of Pfizer in a research note on Monday, July 31st. Finally, BMO Capital Markets upgraded shares of Pfizer from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $33.00 to $37.00 in a research note on Wednesday, August 2nd. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $37.77.

In related news, CEO Ian C. Read sold 96,950 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the transaction, the insider now directly owns 151,474 shares in the company, valued at $5,074,379. The disclosure for this sale can be found here. Company insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.